2′,3′-O-Deacylation of Ribonucleoside DeriVatiVes
1-yl)purine25 (1a) by method A at ambient temperature for 2 h gave
2a (75%): 1H NMR (CD3OD) δ 2.08 (s, 3H), 4.29-4.45 (m, 4H),
4.84 (t, J ) 4.9 Hz, 1H), 6.15 (d, J ) 4.4 Hz, 1H), 7.18 (d, J ) 1.0
Hz, 1H), 8.35 (t, J ) 1.5 Hz, 1H), 8.58 (s, 1H), 8.73 (s, 1H), 9.09
(s, 1H); 13C NMR δ 20.9, 65.0, 72.0, 75.2, 83.7, 90.9, 118.9, 124.3,
130.6, 138.8, 146.3, 146.4, 153.3, 154.8, 172.5; MS m/z 383 (100%,
M + Na+); HMRS Calcd for C15H16N6O5Na: 383.1080, Found:
383.1088.
9-(5-O-Acetyl-â-D-ribofuranosyl)-6-(2,5-dimethylpyrrol-1-yl)-
purine (2b). Treatment of 9-(2,3,5-tri-O-acetyl-â-D-ribofuranosyl)-
6-(2,5-dimethylpyrrol-1-yl)purine26 (1b) by method A at ambient
temperature for 1.5 h gave 2b (71%): 1H NMR δ 2.05 (s, 3H),
2.16 (s, 6H), 4.02 (br s, 1H), 4.33-4.43 (m, 4H), 4.60 (t, J ) 4.2
Hz, 1H), 4.99 (br s, 1H), 5.94 (s, 2H), 6.10 (t, J ) 3.9 Hz, 1H),
8.33 (s, 1H), 8.89 (s, 1H); 13C NMR δ 13.4, 20.7, 63.5, 70.7, 74.6,
82.7, 90.0, 109.1, 129.1, 129.8, 143.7, 150.2, 152.1, 152.7, 170.7;
MS m/z 410 (100%, M + Na+); HMRS Calcd for C18H21N5O5Na:
410.1440, Found: 410.1436.
5′-O-Acetyl-6-N-trityladenosine (2c). Method A. Treatment of
1c by method A at ambient temperature for 2 h gave 2c (66%):
1H NMR δ 1.98 (s, 3H), 4.12-4.48 (m, 7H), 5.89 (d, J ) 4.9 Hz,
1H), 6.18 (br s, 1H), 7.14 (s, 1H), 7.20-7.34 (m, 15H), 7.95 (s,
1H); 13C NMR δ 20.6, 63.2, 70.5, 71.3, 74.8, 82.3, 89.8, 120.8,
126.8, 127.7, 128.8, 138.1, 144.5, 147.6, 151.7, 153.9, 170.4; MS
m/z 574 (100%, M + Na+); HMRS Calcd for C31H29N5O5Na:
574.2066, Found: 574.2053.
75.9, 82.9, 92.4, 94.6, 127.6, 128.4, 128.6, 140.0, 143.5, 156.2,
165.5, 173.6; MS m/z 564 (100%, M + Na+); HMRS Calcd for
C31H31N3O6Na: 564.2110, Found: 564.2124.
5′-O-Propionylcytidine (6f). Treatment of 5f by method B at
ambient temperature for 2.5 h gave 6f (84%): 1H NMR (DMSO-
d6) δ 1.04 (t, J ) 7.6 Hz, 3H), 2.37 (q, J ) 7.5 Hz, 2H), 3.89-
4.00 (m, 3H), 4.18 (dd, J ) 5.4, 11.8 Hz, 1H), 4.27 (dd, J ) 2.9,
11.8 Hz, 1H), 5.22 (br s, 1H), 5.43 (br s, 1H), 5.74 (d, J ) 7.8 Hz,
1H), 5.76 (d, J ) 3.9 Hz, 1H), 7.19 (br s, 1H), 7.24 (br s, 1H),
7.59 (d, J ) 7.9 Hz, 1H); 13C NMR (DMSO-d6) δ 9.0, 26.7, 63.7,
69.7, 73.4, 80.4, 90.0, 94.2, 141.3, 155.2, 165.6, 173.5; MS m/z
322 (100%, M + Na+); HMRS Calcd for C12H17N3O6Na: 322.1010,
Found: 322.1014.
5′-O-Isobutyrylcytidine (6g). Treatment of 5g by method B at
60 °C for 1 h gave 6g (83%): 1H NMR (DMSO-d6) δ 1.10 (t, J )
6.8 Hz, 6H), 2.54-2.62 (m, 1H), 3.89-4.00 (m, 3H), 4.19 (dd, J
) 3.9, 12.2 Hz, 1H), 4.26 (dd, J ) 2.9, 12.2 Hz, 1H), 5.21 (d, J )
6.4 Hz, 1H), 5.43 (d, J ) 5.4 Hz, 1H), 5.73 (d, J ) 7.3 Hz, 1H),
5.76 (d, J ) 3.9 Hz, 1H), 7.18 (br s, 1H), 7.22 (br s, 1H), 7.59 (d,
J ) 7.3 Hz, 1H); 13C NMR (DMSO-d6) δ 19.3, 19.4, 34.6, 64.5,
71.2, 76.1, 82.6, 92.0, 95.8, 142.0, 157.4, 167.2, 177.0; MS m/z
314 (100%, M + H+); HMRS Calcd for C13H20N3O6: 314.1347,
Found: 314.1352.
5′-O-(4-Methylbenzoyl)uridine (6l). Treatment of 5l by method
B at 60 °C for 1.5 h gave 6l (73%): 1H NMR (DMSO-d6) δ 2.40
(s, 3H), 4.06-4.18 (m, 3H), 4.44 (dd, J ) 5.4, 11.7 Hz, 1H), 4.54
(dd, J ) 2.9, 11.7 Hz, 1H), 5.39 (br s, 1H), 5.54 (d, J ) 8.3 Hz,
1H), 5.56 (br s, 1H), 5.79 (d, J ) 4.4 Hz, 1H), 7.37 (d, J ) 8.3 Hz,
2H), 7.64 (d, J ) 7.8 Hz, 1H), 7.88 (d, J ) 7.8 Hz, 2H), 11.40 (br
s, 1H); 13C NMR (DMSO-d6) δ 21.2, 64.1, 69.7, 72.8, 81.1, 89.0,
101.9, 126.7, 129.3, 129.5, 140.8, 144.0, 150.6, 163.1, 165.6; MS
m/z 363 (100%, M + H+); HMRS Calcd for C17H19N2O7:
363.1187, Found: 363.1183.
3-(5-O-Benzoyl-â-D-ribofuranosyl)furo[2,3-d]pyrimidin-2(3H)-
one (6p). Treatment of 5p by method B at ambient temperature
for 0.5 h gave 6p (62%): 1H NMR (DMSO-d6) δ 4.09-4.14 (m,
2H), 4.28-4.32 (m, 1H), 4.58 (dd, J ) 5.4, 12.7 Hz, 1H), 4.71
(dd, J ) 2.4, 12.2 Hz, 1H), 5.66 (br s, 1H), 5.87 (s, 1H), 5.96 (br
s, 1H), 6.39 (dd, J ) 1.0, 2.4 Hz, 1H), 7.54 (t, J ) 7.3 Hz, 2H),
7.68-7.71 (m, 1H), 8.01 (d, J ) 8.3 Hz, 2H), 8.50 (s, 1H), 8.57
(s, 1H); 13C NMR (DMSO-d6) δ 63.9, 68.9, 74.7, 79.2, 80.7, 92.6,
105.0, 128.8, 129.3, 133.5, 138.9, 144.9, 153.8, 165.6, 166.0, 171.4;
MS m/z 373 (100%, M + H+); HMRS Calcd for C18H17N2O7:
373.1030, Found: 373.1035.
Method B. Treatment of 1c by method B at ambient temperature
for 0.5 h gave 2c (88%) with identical spectral data.
5′-O-Acetyl-6-N,N-di(4-methylbenzoyl)adenosine (2d). Treat-
ment of 1d by method A at ambient temperature for 1 h gave 2d
(39%): 1H NMR δ 2.00 (s, 3H), 2.34 (s, 6H), 3.67 (d, J ) 3.9 Hz,
1H), 4.24-4.36 (m, 4H), 4.57 (m, 1H), 4.95 (d, J ) 3.9 Hz, 1H),
6.00 (d, J ) 4.9 Hz, 1H), 7.14 (d, J ) 7.8 Hz, 4H), 7.73 (d, J )
7.8 Hz, 4H), 8.18 (s, 1H), 8.58 (s, 1H); 13C NMR δ 20.7, 21.6,
63.6, 70.7, 74.4, 82.4, 89.6, 127.5, 129.47, 129.54, 130.9, 143.6,
144.2, 151.9, 152.0, 152.3, 170.7, 172.3; MS m/z 568 (100%, M
+ Na+); HMRS Calcd for C28H27N5O7Na: 568.1808, Found:
568.1804.
2′,3′,5′-Tri-O-propionyl-4-N-tritylcytidine (3e). 1H NMR δ 1.06
(t, J ) 7.3 Hz, 3H), 1.13 (t, J ) 7.3 Hz, 6H), 2.17-2.48 (m, 6H),
4.25-4.38 (m, 3H), 5.04 (d, J ) 7.8 Hz, 1H), 5.26 (t, J ) 5.6 Hz,
1H), 5.34 (t, J ) 4.6 Hz, 1H), 6.11 (d, J ) 3.9 Hz, 1H), 6.93 (br
s, 1H), 7.20-7.36 (m, 16H); 13C NMR δ 8.49, 8.56, 26.79, 26.89,
62.1, 69.0, 70.6, 73.3, 78.9, 88.3, 94.5, 127.3, 128.1, 128.3, 139.7,
143.4, 154.3, 165.1, 172.5, 172.6, 173.1; MS m/z 676 (100%, M
+ Na+); HMRS Calcd for C37H39N3O8Na: 676.2635, Found:
676.2637.
5′-O-Propionyl-4-N-tritylcytidine (4e). Treatment of 3e by
method B at ambient temperature for 2.5 h gave 4e (94%): 1H
NMR δ 1.00 (t, J ) 7.3 Hz, 3H), 2.04-2.19 (m, 2H), 3.61 (br s,
1H), 4.10-4.44 (m, 5H), 5.09 (d, J ) 7.8 Hz, 1H), 5.73 (d, J )
2.9 Hz, 1H), 6.11 (br s, 1H), 7.02 (br s, 1H), 7.22-7.35 (m, 15H),
7.37 (d, J ) 7.8 Hz, 1H); 13C NMR δ 8.9, 27.2, 63.3, 70.8, 71.0,
Acknowledgment. We gratefully acknowledge pharmaceuti-
cal company unrestricted gift funds (M.J.R.), and Brigham
Young University for support of this research.
Supporting Information Available: 1H NMR, 13C NMR, and
mass spectral data for less accessible polyacylated starting materials
and selective deacylation products; representative 1H NMR spectra
(for 4a, 4h, 6h, 6k, 6m, 9); 13C NMR spectra (for 1c, 1d, 2a-d,
3a-g, 3i-k, 4a-k, 5m, 5n, 5p, 6a-n, 6p, 7-9). This material is
(25) Lin, X.; Robins, M. J. Org. Lett. 2000, 2, 3497-3499.
(26) Nowak, I.; Robins, M. J. Org. Lett. 2003, 5, 3345-3348.
JO0600104
J. Org. Chem, Vol. 71, No. 8, 2006 3081